Key Takeaways
- A brutal quarter, but framed as a trough: Revenue collapsed 40% YoY as the twin hits of post-COVID normalization and generic pricing pressure landed simultaneously. Management insists the worst is past, pointing to volume growth and easing raw material costs.
- The margin reset is deeper than expected: Gross margins fell ~7 percentage points QoQ, crushed by API price realizations down 5–10% and raw material costs that doubled over two years. The path back to 40% EBITDA is a two-year journey, not a quick snapback.
- Contrast media is the next big bet: Long-term supply agreements are being negotiated with a handful of global customers for iodine and gadolinium APIs, with commercial supply expected from Q1 FY2024. Management is aiming for numbers "much larger" than ₹100–200 crores.
- Kakinada is now real, but years away from revenue: All clearances are in hand, 500 acres are secured, and a boundary wall is going up. Phase 1 will cost ₹1,000 crores, but the facility won't be ready for 2–3 years and will first produce for non-regulated markets.
- What to watch next quarter: Whether the promised QoQ margin improvement actually materializes, any sign that generic pricing pressure is easing rather than just being called out as easing, and the pace of commercial ramp-up on the two completed fast-track custom synthesis projects.
The Margin Shock: What Happened and the Path Back
- Generic pricing cracked: API price realizations fell 5–10% for some products as competitors who were locked out during COVID returned to the market with stock. The pressure was across the portfolio, with newer products potentially facing more as competitor inventory unwinds.
- Raw materials bit hard: Some input prices doubled over the prior two years, and the company procured at those highs. Prices are now softening on new contracts, but the high-cost inventory still needs to work through. Lithium and iodine prices are expected to keep rising.
- Product mix turned hostile: The generics-to-custom-synthesis mix shifted to 60:40 for the quarter from 55:45 for 9M, meaning more exposure to the segment where nobody compensates for raw material cost increases. Custom synthesis margins held up better because customers sometimes share the pain.
- Post-COVID reorientation added cost: Coming off high-margin, high-productivity COVID drug production meant modifying and reorienting assets back to current generic products, a process that incurred its own costs.
- Other expenses spiked on safety and maintenance: Planned rebuilds of plant structures originally built in 1995, replacement of old safety systems including pipelines and electrical cables, and higher taxation all hit in the quarter.
- The recovery timeline is measured in years, not quarters: Management does not expect to reach 40% EBITDA margins in the next 3–4 quarters, though says it is possible. The realistic target is a return to those levels within two years, helped by new chemistry efforts that minimize material consumption and increase throughput.
Dr. Murali K. Divi: "We are not talking about immediately in the next 3, 4 quarters to reach such level. But definitely, it is possible. ... I think we will see in the next 2 years, probably we should be back with such."
Volume: The Silver Lining Under the Pricing Storm
- Volume growth is real and broad-based: Despite the pricing carnage, top generic products continue to grow primarily on volume, with some seeing 50%, 60%, even 70% volume improvements. Double-digit volume growth is foreseen to continue.
- Demand is shifting back to Divis: Additional demand is coming from customers who previously bought elsewhere and are now facing issues with those suppliers. Products are expanding and the company is gaining share even as prices fall.
- The COVID comparison is now irrelevant: Management explicitly warned against comparing current performance to the exceptional opportunity of the prior 5–6 quarters, urging investors to benchmark against pre-COVID business levels instead. Normal growth is what they see ahead.
- Capacity utilization has headroom: Current occupancy is 75–77%, leaving 20–25% free capacity. It will take about two years to get the full benefit out of new capacities as qualifications are completed and agency clearances are awaited.
Dr. Murali K. Divi: "We cannot compare with the previous 5, 6 quarters, where we had exceptional opportunity. We used the speed, took challenges and you see the pre-COVID business, I think we are seeing normal growth in the coming quarters and profitability should improve quarter-on-quarter."
Contrast Media: The Next Growth Engine Takes Shape
- The market is concentrated and growing fast: Only a handful of customers worldwide consume contrast media APIs, both iodine and gadolinium compounds. The market is growing at a minimum of 10% annually, with each product needing about 2,500–3,000 tons and an extra ~300 tons of new demand every year.
- Long-term agreements are in negotiation: Divis is discussing long-term supply agreements with the majority of these global customers. In most cases, the deals are for direct APIs; in a few, they are for N-minus-1 or N-minus-2 intermediates.
- The custom synthesis contrast media project is live: The project has been implemented, quantification is done, and commercial production has just been entered. Two big fast-track custom synthesis projects have also been completed and validated, both now in commercial ramp-up.
- Commercial supply starts Q1 FY2024: Good numbers from contrast media are expected from Q1 FY2024 onwards, by which time all regulatory clearances should be in hand for both the custom synthesis project and the company's own generics.
- The ambition is large: When asked if the opportunity is in the ₹100–200 crore range, management pushed back, saying it should be bigger because the business is much larger and they are aiming at bigger numbers.
Dr. Murali K. Divi: "There are not many customers who would consume the contrast media, both iodine compound, gadolinium compounds. There are only a handful in the whole world. And with the majority of them….. we are discussing for long-term agreement for supply of these APIs."
Kakinada: The Long-Dated Capacity Call Option
- Land and clearances are secured: The Unit 3 facility near Kakinada has received all necessary government clearances, and the 500-acre land parcel has been handed over. Construction of the boundary wall has begun and project planning for starting materials, intermediates, and APIs is underway.
- Phase 1 will cost ₹1,000 crores: Construction is expected to go into full swing in the next 1–2 quarters. Teams for construction and fabrication have already been moved to the site.
- The facility is 2–3 years from readiness: Management expects it to be ready anytime after two years. Initially, it will produce starting materials with difficult chemistry, some advanced intermediates, and some APIs. APIs will first be sold to other markets while qualifying for regulated markets.
- Why now if existing units have headroom: Existing investments in Unit 1 and Unit 2 mean immediate capacity from Kakinada is not needed, but it will be required once current capacity is absorbed as new projects come in. Raw materials, starting materials, and intermediates from Kakinada can also be consumed in existing products to increase capacity.
- Kakinada's share of CWIP is minimal: Of the ₹575 crores in capital work-in-progress, only a small amount relates to Kakinada. The bulk is in the existing SEZ and EOU units. The specific Kakinada amount was not disclosed.
The Pipeline Beyond Contrast Media
- Custom synthesis opportunities are at an all-time high: Management stated they have never seen so many opportunities coming from big pharma across all therapeutic segments. During COVID, big pharma prioritized COVID drugs over other segments; now they are stepping on the pedal for everything else.
- Small-volume products will scale dramatically: In the next two years, products currently in small volumes are expected to go into multiple tens of tons or higher as they are implemented in groups.
- NCE-based molecules are progressing toward launches: Drug master files have been submitted for some NCE-based molecules, others are being readied. Customers have sampled and purchased quantities for formulation purposes and stability studies to submit to the FDA. The opportunity is tied to $20 billion of products expiring between 2023 and 2025.
- FY2025 is the volume year for NCEs: Even if launches start in FY2024, day-one volumes will not be very big. FY2025 should see good volumes for sure.
- New chemistry capabilities are being built: Plans are in place to invest in vapor-phased chemistry, continuous flow chemistry, photochemistry, gadolinium compounds, and peptide building blocks. Management expects to be very busy implementing these over the next 6–8 quarters.
- The growth ambition is unconstrained: When asked if the company will return to its historical 10–15% growth rate, management's one-line response captured the mood.
Dr. Murali K. Divi: "Why not more?"
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Margin recovery | Gross margins to improve; profitability to increase QoQ | Coming quarters |
| EBITDA margin normalization | Return to ~40% EBITDA levels | Within 2 years |
| Contrast media commercial supply | Commercial supply for both custom synthesis project and own generics to start | Q1 FY2024 |
| Fast-track CS projects ramp-up | Two completed projects to fully ramp; some values visible through Q4 | Full ramp by Q1 FY2024 |
| NCE-based molecule volumes | Good volumes from NCE launches | FY2025 |
| Kakinada Phase 1 construction | Full swing construction to begin | Next 1–2 quarters |
| Kakinada facility readiness | Facility ready to produce starting materials, intermediates, APIs | 2–3 years |
| Double-digit growth | Both sales and profitability to grow double digits, enabled by six growth engines | Ongoing (no quarter specified) |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Consolidated total revenue | ₹1,822 cr, vs ₹2,510 cr in Q3 FY22 |
| Material consumption | 43% of sales revenue, due to change in product mix |
| Profit before tax | ₹436 cr |
| Effective tax rate | 29% |
| Profit after tax | ₹307 cr |
| Exports share | 87% of revenue |
| Europe and America export share | 69% of revenue for the quarter, 70% for 9M FY23 |
| Generics to custom synthesis mix | 60% to 40% for the quarter, 55% to 45% for 9M FY23 |
| Forex gain | ₹47 cr for the quarter, ₹134 cr for 9M FY23 |
| Constant currency growth | negative 40% for the quarter, negative 17% for 9M FY23 |
| Nutraceutical business revenue | ₹160 cr for the quarter, ₹509 cr for 9M FY23 |
| Cash on books | ₹3,849 cr as of 31st December |
| Receivables | ₹1,659 cr as of 31st December |
| Inventories | ₹2,981 cr as of 31st December |
| Capital work-in-progress | ~₹575 cr at end of quarter |
| Capacity occupancy | 75% to 77%, implying at least 20% to 25% free capacity |
| API price decline range | 5% to 10% on some APIs |
| Gross margin QoQ change | down almost 7 percentage points QoQ |
| Custom synthesis revenue (per analyst's math) | ₹675 cr this quarter, vs ₹680 cr in Q3 FY21 (per an analyst's math) |